Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference
26 Septembre 2022 - 2:00PM
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology
company developing targeted therapeutics to treat metastatic
disease, today announced that Gail McIntyre, Ph.D., DABT, Chief
Executive Officer and Rudy Howard, Chief Financial Officer will
participate in the Cantor Fitzgerald Oncology & HemOnc
Conference on September 28, 2022 at the Lotte New York Palace
Hotel, New York, N.Y.
Dr. McIntyre will participate in a panel discussion titled
“Companies with Key Catalysts Over the Next 12-18 Months” on
Wednesday, September 28, at 10:40 am ET.
About AraviveAravive, Inc. is a late
clinical-stage oncology company developing targeted therapeutics to
treat metastatic disease. Our lead product candidate, batiraxcept
(formerly AVB-500), is an ultra-high affinity decoy protein that
binds to GAS6, the sole ligand that activates AXL, thereby
inhibiting metastasis and tumor growth, and restoring sensitivity
to anti-cancer agents. Batiraxcept has been granted Fast Track
Designation by the U.S. FDA and Orphan Drug Designation by the
European Commission in platinum-resistant recurrent ovarian cancer.
Batiraxcept is in an active registrational Phase 3 trial in
platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial
in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2
trial in pancreatic adenocarcinoma (NCT04983407). The Company is
based in Houston, Texas and received a Product Development Award
from the Cancer Prevention & Research Institute of Texas
(CPRIT) in 2016. Additional information at www.aravive.com.
Contact:Lenne GreenAravive, Inc.(936)
355-1910ir@aravive.com
Aravive (NASDAQ:ARAV)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Aravive (NASDAQ:ARAV)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024